announcement, page-3

KarmelSonix issues more shares; clinical studies
13:25, Friday, 17 August 2007

Sydney - Friday - August 17: (RWE Australian Business News) -
KarmelSonix Ltd (ASX:KSX) has issued a further 8.5m shares in respect of
the recently announced placement and further conversion of options into
ordinary shares. These shares primarily are in respect of subscriptions
received from Israeli-based investors.
Directors also announced the initiation of a series of clinical
validation studies in three key laboratories and clinics in the US.
The studies' results will serve to enhance the overall marketing
activities of the WIM-PC and its derivatives products.
The following is a list of the agreed-upon studies:
* Use of the WIM technology to perform Methacholine bronchial
provocation tests in poorly cooperating patients in the diagnostic
work-up of an asthma patient. [Principal Investigator: Prof Sheldon
Spector, UCLA, Los Angeles]
* Acoustic nocturnal asthma monitoring to determine presence of
wheeze activity during a 36-hour stay in the sleep lab. This study is
done as part of a basic study to investigate the expression of eight
"clock" genes and their effects on the circadian rhythms in asthma
patients. [PI: Prof Lisa Wolfe, Northwestern University and Northwestern
Memorial Hospital, Chicago]
* A study to establish and optimise the use of "Wheezometery"
in the clinical management of pre-school children with asthma. The study
will set and validate test procedures and criteria based on wheeze
monitoring before and after administration of a short-acting
bronchodilator. [PI: Prof Adrian Prestridge, Children's Memorial
Hospital, Chicago]
These and subsequent clinical studies are intended to establish
the use of KarmelSonix technology as the standard-of-care in the
monitoring and management of asthma patients.
Also, the company reported commercial negotiations were at an
advanced stage in respect of the further development, deployment and
distribution of the KarmelSonix product range, including the WIM-PC and
other products under development.